Evidence map›Paper›PMID 30659809›Full record

SynthesisThe American journal of medicine2019

Periprocedural Bridging in Patients with Venous Thromboembolism: A Systematic Review.

Christine Baumgartner, Ivan de Kouchkovsky, Evans Whitaker, Margaret C Fang

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in The American journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Perioperative consultative hematology: can you clear my patient for a procedure?Hematology. American Society of Hematology. Education Program · 2021
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Christine BaumgartnerDivision of Hospital Medicine, University of California, San Francisco; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Ivan de KouchkovskyDivision of Hospital Medicine, University of California, San Francisco.
Evans WhitakerUCSF Medical Library, University of California, San Francisco.
Margaret C FangDivision of Hospital Medicine, University of California, San Francisco. Electronic address: Margaret.Fang@ucsf.edu.
University of California, San Francisco · USUniversity Hospital of Bern · CH

Funding

Anticoagulation Treatment and Long-Term Outcomes After Venous ThromboembolismR01HL103820 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FANG, MARGARET C. · 2010 to 2014
$3.6M
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patientsK24HL141354 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FANG, MARGARET C. · 2018 to 2022
$731k
NHLBI NIH HHS K24 HL141354NHLBI NIH HHS R01 HL103820
6 · The paper itself

Abstract

backgroundVitamin K antagonists (VKA) are the most widely used anticoagulants, and bridging is commonly administered during periprocedural VKA interruption. Given the unclear benefits and risks of periprocedural bridging in patients with previous venous thromboembolism, we aimed to assess recurrent venous thromboembolism and bleeding outcomes with and without bridging in this population.

methodsWe performed a systematic review searching the PubMed and Embase databases from inception to December 7, 2017 for randomized and nonrandomized studies that included adults with previous venous thromboembolism requiring VKA interruption to undergo an elective procedure, and that reported venous thromboembolism or bleeding outcomes. Quality of evidence was graded by consensus.

resultsWe included 28 cohort studies (20 being single-arm cohorts) with, overall, 6915 procedures for analysis. In 27 studies reporting perioperative venous thromboembolism outcomes, the pooled incidence of recurrent venous thromboembolism with bridging was 0.7% (95% confidence interval [CI], 0.4%-1.2%) and 0.5% (95% CI, 0.3%-0.8%) without bridging. Eighteen studies reported major or nonmajor bleeding outcomes. The pooled incidence of any bleeding was 3.9% (95% CI, 2.0%-7.4%) with bridging and 0.4% (95% CI, 0.1%-1.7%) without bridging. In bridged patients at high thromboembolic risk, the pooled incidence for venous thromboembolism was 0.8% (95% CI, 0.3%-2.5%) and 7.5% (95% CI, 3.1%-17.4%) for any bleeding. Quality of available evidence was very low, primarily due to a high risk of bias of included studies.

conclusionsPeriprocedural bridging increases the risk of bleeding compared with VKA interruption without bridging, without a significant difference in periprocedural venous thromboembolism rates.

Indexed as

AnticoagulantsHemorrhageHumansVenous ThromboembolismVitamin KAnticoagulantsVitamin KAnticoagulantsBleedingBridgingPeriproceduralPROSPEROregistration number CRD42017074710Venous thromboembolism

Identifiers

PMID30659809
PMCPMC6588421
OpenAlexW2909870638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.